Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant ExercisesBusiness Wire • 12/30/24
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal CancerBusiness Wire • 12/02/24
Wall Street Analysts Believe Delcath Systems (DCTH) Could Rally 96.84%: Here's is How to TradeZacks Investment Research • 11/05/24
Delcath Systems, Inc. (DCTH) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 11/01/24
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma SubgroupsBusiness Wire • 09/16/24
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma PatientsBusiness Wire • 08/28/24
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment ConferenceBusiness Wire • 08/28/24
Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma PatientsBusiness Wire • 08/27/24
Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver TumorsBusiness Wire • 08/26/24
Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +Seeking Alpha • 08/23/24
Delcath Systems, Inc. (DCTH) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/05/24